NCT00001349

Brief Summary

This study will collect blood plasma and white blood cells for laboratory research using a procedure called apheresis. Apheresis is a method of collecting larger quantities of certain blood components than can safely be collected through a simple blood draw. Patients 7 years of age and older with a parasitic infection or condition associated with a parasitic infection (i.e., elevated levels of IgE antibodies or of a type of white cell called eosinophils) who are currently enrolled in a NIH clinical research protocol may be eligible for this study. Relatives of patients and normal healthy volunteers will also be enrolled. Candidates will have a medical history, physical examination and blood tests. Individuals weighing less than 25 kilograms (55 pounds) may not participate. Participants will undergo one of the following two apheresis procedures:

  • Automated pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through a cell separator machine. The plasma (liquid part of the blood) and white cells are extracted, and the red cells are re-infused into the donor through a needle in the other arm. The procedure takes 1 to 2 hours.
  • Manual pheresis Whole blood is drawn through a needle placed in an arm vein and circulated through the cell separator machine. The red blood cells are separated from the rest of the blood and returned to the donor through the same needle. Usually only one needle stick is required and the procedure takes from 30 to 45 minutes. This method is used only in individuals who weigh less than 35 kg (77 pounds).

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
205

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Mar 1993

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 23, 1993

Completed
6.6 years until next milestone

First Submitted

Initial submission to the registry

November 3, 1999

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 4, 1999

Completed
22 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 9, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 9, 2021

Completed
Last Updated

November 10, 2021

Status Verified

November 1, 2021

Enrollment Period

28.7 years

First QC Date

November 3, 1999

Last Update Submit

November 9, 2021

Conditions

Keywords

PlasmapheresisLymphocytesEosinophilsNeutrophils

Outcome Measures

Primary Outcomes (1)

  • To obtain leukocytes,platelets, and plasma from subjects already enrolled on other NIAID/LPD protocols.

    Leukocytes, platelets, and plasma will be collected.

    Ongoing as this is a method to collect cells from subjects enrolled on other LPD protocols

Study Arms (1)

1

Donors first admitted to another approved clinical research protocol of the NIAID before having the apheresis procedures described in this protocol.

Eligibility Criteria

Age8 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Any subject enrolled on an existing !RB-approved LPD protocol may be asked to participate and thereby undergo apheresis.

You may qualify if:

  • Enrolled on another LPD protocol.
  • Weight greater than or equal to 25 kg
  • Willingness to participate

You may not qualify if:

  • Age less than 7 years
  • Weight less than 25 kg
  • Cardiovascular instability
  • Hct less than 30
  • Inadequate venous access
  • PTT or PT greater than 1.5 normal
  • Pregnancy
  • Women who are actively breastfeeding
  • Other condition which the attending physician or Apheresis Unit staff considers a contraindication to the procedure
  • For Hetastarch procedure
  • Hypertension
  • Evidence of fluid retention

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Boyd A, Ribeiro JM, Nutman TB. Human CD117 (cKit)+ innate lymphoid cells have a discrete transcriptional profile at homeostasis and are expanded during filarial infection. PLoS One. 2014 Sep 25;9(9):e108649. doi: 10.1371/journal.pone.0108649. eCollection 2014.

    PMID: 25255226BACKGROUND
  • Chatterjee S, Clark CE, Lugli E, Roederer M, Nutman TB. Filarial infection modulates the immune response to Mycobacterium tuberculosis through expansion of CD4+ IL-4 memory T cells. J Immunol. 2015 Mar 15;194(6):2706-14. doi: 10.4049/jimmunol.1402718. Epub 2015 Feb 9.

    PMID: 25667413BACKGROUND
  • Santiago Hda C, Ribeiro-Gomes FL, Bennuru S, Nutman TB. Helminth infection alters IgE responses to allergens structurally related to parasite proteins. J Immunol. 2015 Jan 1;194(1):93-100. doi: 10.4049/jimmunol.1401638. Epub 2014 Nov 17.

    PMID: 25404363BACKGROUND

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Leukocytes, platelets and plasma will be collected. Since this protocol only allows for apheresis to be performed on participants enrolled on another LPD protocol, any biological samples collected will be covered by the other, individual protocol on which the participant is enrolled.

Study Officials

  • Thomas B Nutman, M.D.

    National Institute of Allergy and Infectious Diseases (NIAID)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 3, 1999

First Posted

November 4, 1999

Study Start

March 23, 1993

Primary Completion

November 9, 2021

Study Completion

November 9, 2021

Last Updated

November 10, 2021

Record last verified: 2021-11

Locations